Phase 4
Completed N=28
Vildagliptin Versus Dapagliflozin on Glucagon
Source: ClinicalTrials.gov NCT02475070 ↗Enrolled (actual)
28
Serious AEs
0.0%
Results posted
May 2019
Primary outcomePrimary: Glucagon Response to Meal — 39.0; 38.8 nmol/l min
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The aim of the study is to assess if vildagliptin and dapagliflozin have dissociated effects on glucagon secretion after a mixed meal ingestion in metformin-treated subjects with type 2 diabetes and whether this is associated with effects on glucose homeostasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glucagon Response to Meal |
39.0; 38.8 | — |
| SECONDARY Incretin Hormones |
3.8; 3.7 | — |
Eligibility Criteria
Inclusion Criteria
- Written consent has been given.
- Patients with type 2 diabetes treated with a stable dose of metformin during the last three months
- Age 20-70 years.
- HbA1c 6.5-8.5% (48-67 mmol/mol) at visit 1.
- Ability to complete the study
Exclusion Criteria
- Use of other glucose-lowering therapy than metformin within three months prior to visit 1.
- A history of any secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.
- Type 1 diabetes, positive GAD antibodies
- Estimated glomerular filtration rate 7 consecutive days of treatment) within 8 weeks prior to visit 1.
- Use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable for the study
- Hypersensitivity to vildagliptin or dapagliflozin or any compound in the tablet core
Data sourced from ClinicalTrials.gov (NCT02475070). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.